Ortho-Novum Tablets (norethindrone/ethinyl estradiol) and Modicon 28 Tablets (norethindrone/ethinyl estradiol)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

October 2015

Summary View


Thromboembolic Disorders and Other Vascular Problems


  • edited...The risk of thromboembolic disease associated with oral contraceptives gradually disppears after combined oral contraceptive (COC) use is stopped. VTE risk is highest in the first year of use and when restarting hormonal contraception after a break of four weeks or longer.

Page Last Updated: 11/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English